ZTS Stock Forecast 2025-2026
Distance to ZTS Price Targets
ZTS Price Momentum
🤔 Considering Zoetis (ZTS)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest ZTS Stock Price Targets & Analyst Predictions
Based on our analysis of 22 Wall Street analysts, ZTS has a bullish consensus with a median price target of $200.00 (ranging from $171.00 to $244.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $161.26, the median forecast implies a 24.0% upside. This outlook is supported by 15 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Balaji Prasad at Barclays, projecting a 51.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ZTS Analyst Ratings
ZTS Price Target Range
Latest ZTS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ZTS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 27, 2025 | Piper Sandler | David Westenberg | Overweight | Maintains | $205.00 |
| Feb 14, 2025 | Barclays | Balaji Prasad | Overweight | Maintains | $244.00 |
| Feb 14, 2025 | Morgan Stanley | Erin Wright | Overweight | Maintains | $238.00 |
| Feb 10, 2025 | Piper Sandler | David Westenberg | Overweight | Maintains | $200.00 |
| Jan 29, 2025 | Morgan Stanley | Erin Wright | Overweight | Maintains | $243.00 |
| Jan 7, 2025 | Stifel | Jonathan Block | Buy | Maintains | $180.00 |
| Dec 10, 2024 | UBS | Neutral | Initiates | $0.00 | |
| Dec 9, 2024 | UBS | Neutral | Initiates | $196.00 | |
| Dec 2, 2024 | Leerink Partners | Daniel Clark | Outperform | Initiates | $215.00 |
| Oct 11, 2024 | JP Morgan | Chris Schott | Overweight | Maintains | $230.00 |
| Sep 18, 2024 | Stifel | Jonathan Block | Buy | Maintains | $210.00 |
| Aug 27, 2024 | Stifel | Jonathan Block | Buy | Maintains | $200.00 |
| Aug 14, 2024 | Piper Sandler | David Westenberg | Overweight | Maintains | $210.00 |
| Aug 12, 2024 | BTIG | Mark Massaro | Buy | Maintains | $225.00 |
| Aug 7, 2024 | Barclays | Overweight | Maintains | $0.00 | |
| Aug 5, 2024 | Stifel | Jonathan Block | Buy | Maintains | $200.00 |
| Jul 25, 2024 | BTIG | Mark Massaro | Buy | Initiates | $220.00 |
| May 8, 2024 | HSBC | Morten Herholdt | Buy | Maintains | $225.00 |
| May 6, 2024 | Goldman Sachs | Nathan Rich | Buy | Maintains | $196.00 |
| Apr 30, 2024 | Stifel | Jonathan Block | Buy | Maintains | $180.00 |
Zoetis Inc. (ZTS) Competitors
The following stocks are similar to Zoetis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Zoetis Inc. (ZTS) Financial Data
Zoetis Inc. has a market capitalization of $72.21B with a P/E ratio of 29.5x. The company generates $9.26B in trailing twelve-month revenue with a 26.9% profit margin.
Revenue growth is +4.7% quarter-over-quarter, while maintaining an operating margin of +33.1% and return on equity of +51.1%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Zoetis Inc. (ZTS) Business Model
About Zoetis Inc.
Develops medicines and vaccines for animal healthcare.
Zoetis generates revenue through the development, manufacture, and sale of a wide range of veterinary medicines and vaccines targeted at pets and livestock. The company's strong portfolio, aimed at veterinarians and livestock producers, supports animal health and productivity, capitalizing on trends in pet ownership and livestock management.
Founded as a spinoff from Pfizer in 2013, Zoetis operates in over 100 countries and focuses on continuous research and innovation to meet the changing demands of animal health. The company’s strategic partnerships and initiatives contribute to a sustainable future in the animal health industry, enhancing its market position.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
13,800
CEO
Ms. Kristin C. Peck
Country
United States
IPO Year
2013
Website
www.zoetis.comZoetis Inc. (ZTS) Latest News & Analysis
Zoetis Inc. (ZTS) CFO Wetteny Joseph Hosts Barclays 27th Annual Global Healthcare (Transcript)
4 days agoZoetis Inc. (NYSE:ZTS) will participate in the Barclays 27th Annual Global Healthcare Conference on March 11, 2025, at 10:30 AM ET, featuring CFO Wetteny Joseph.
Zoetis' participation in a major healthcare conference signals its visibility in the market and potential investor interest, influencing stock performance and investor sentiment.
Zoetis (ZTS) closed at $170.37, up 1.87% from the previous trading day.
The 1.87% increase in Zoetis' share price indicates positive market sentiment, potentially signaling growth and investor confidence, impacting future investment decisions.
The SPDR S&P 500 ETF Trust had a downturn in February but remains positive for 2025. March's top 15 dividend stocks yield 1.13% and are 25% undervalued, with a 10.63% CAGR since 2020.
The SPDR S&P 500 ETF Trust's recovery and the undervaluation of top dividend stocks indicate potential growth and income opportunities, enhancing portfolio strategies for 2025.
Zoetis Inc. (NYSE: ZTS) will participate in the BofA Securities 2025 Animal Health Summit on February 27, 2025, at 1:20 PM ET, with CFO Wetteny Joseph presenting.
Zoetis Inc. participating in the BofA Securities Animal Health Summit signals its commitment to investor relations and may provide insights into future growth strategies, impacting stock perceptions.
A Once-in-a-Decade Opportunity: 1 Magnificent S&P 500 Dividend Stock Down 36% to Double Up on Right Now
20 days agoZoetis (ZTS), an animal healthcare company, is highlighted as a promising stock with potential for market-beating performance.
Zoetis' market-beating potential signals strong growth prospects, attracting investor interest in a resilient sector, which could lead to increased stock demand and higher valuations.
Zoetis CEO on bird flu vaccine
25 days agoZoetis obtained a conditional license for its bird flu vaccine from the USDA to combat the disease in poultry, according to CEO Kristin Peck.
Zoetis' conditional license for a bird flu vaccine could boost revenue from poultry farmers seeking protection, enhancing the company's growth prospects and market position in animal health.
Frequently Asked Questions About ZTS Stock
What is Zoetis Inc.'s (ZTS) stock forecast for 2025?
Based on our analysis of 22 Wall Street analysts, Zoetis Inc. (ZTS) has a median price target of $200.00. The highest price target is $244.00 and the lowest is $171.00.
Is ZTS stock a good investment in 2025?
According to current analyst ratings, ZTS has 15 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $161.26. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ZTS stock?
Wall Street analysts predict ZTS stock could reach $200.00 in the next 12 months. This represents a 24.0% increase from the current price of $161.26. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Zoetis Inc.'s business model?
Zoetis generates revenue through the development, manufacture, and sale of a wide range of veterinary medicines and vaccines targeted at pets and livestock. The company's strong portfolio, aimed at veterinarians and livestock producers, supports animal health and productivity, capitalizing on trends in pet ownership and livestock management.
What is the highest forecasted price for ZTS Zoetis Inc.?
The highest price target for ZTS is $244.00 from Balaji Prasad at Barclays, which represents a 51.3% increase from the current price of $161.26.
What is the lowest forecasted price for ZTS Zoetis Inc.?
The lowest price target for ZTS is $171.00 from at , which represents a 6.0% increase from the current price of $161.26.
What is the overall ZTS consensus from analysts for Zoetis Inc.?
The overall analyst consensus for ZTS is bullish. Out of 22 Wall Street analysts, 15 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $200.00.
How accurate are ZTS stock price projections?
Stock price projections, including those for Zoetis Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
